Keyphrases
Positron Emission Tomography
78%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
67%
Receptor Binding
58%
AE105
51%
5-HT2A Receptor
51%
Serotonin 2A Receptor (5-HT2AR)
46%
Serotonin Transporter
39%
NODAGA
33%
Active Sites
33%
Gallium-68
33%
Tissue Factor
32%
Positron Emission Tomography Tracers
29%
Angiogenesis
27%
PET Imaging
27%
Positron Emission Tomography-computed Tomography (PET-CT)
24%
Human Xenografts
23%
Cancer Xenograft
23%
Radioligand
22%
Tissue Factor Expression
21%
PET Tracer
21%
Tumor
20%
Tumor Uptake
20%
Xenograft Tumor
19%
Tracer Uptake
18%
Radiosynthesis
17%
C(RGDyK)
17%
Dosimetry
17%
18F-FLT
16%
In Vivo Evaluation
16%
Serotonergic System
16%
Integrin
15%
In Vivo Imaging
15%
Mood Disorders
15%
First-in-human
14%
Non-invasive Assessment
13%
Serotonin 2A
13%
5-HT2A Receptor Agonist
13%
Prostate Cancer
13%
Dynamic PET
13%
Serum Serotonin
12%
Fluorine-18
12%
First-in-human Study
12%
Human Cancer
12%
18F-labeled
11%
Lutetium-177 (177Lu)
11%
Aldehydes
11%
Receptor Agonist
11%
Cortisol Awakening Response
11%
Minipig
11%
Oxime
11%
Medicine and Dentistry
Positron Emission Tomography
100%
Neoplasm
62%
Urokinase Receptor
56%
Radioactive Tracer
55%
Tumor Xenograft
44%
Positron Emission Tomography
44%
Fluorine-18
39%
Tetraxetan
36%
Angiogenesis
24%
Copper 64
22%
Positron Emission Tomography-Computed Tomography
20%
Gallium 68
19%
Dosimetry
19%
Prostate Cancer
17%
Tumor Invasion
17%
Factor VII
16%
Thromboplastin
16%
Integrin
16%
Malignant Neoplasm
14%
Xenograft
13%
Biological Marker
13%
Human Study
12%
Glioblastoma
12%
Metastatic Carcinoma
11%
Lutetium 177
11%
Neuroendocrine Tumor
11%
Ovarian Cancer
11%
Myocardial Infarction
11%
Fluorodeoxyglucose F 18
11%
Clinical Trial
10%
Biodistribution
10%
Gene Expression
9%
Primary Tumor
8%
Cell Proliferation
8%
Treatment Response
7%
Diagnosis
7%
Cancer Cell
7%
In Vitro
7%
Molecular Imaging
6%
Breast Cancer
6%
Tumor Imaging
6%
Patient Monitoring
6%
Positron Emission Tomography - Magnetic Resonance Imaging
6%
Motor Performance
5%
Radionuclide Therapy
5%
Peptide Receptor
5%
General Anesthesia
5%
Gleason Score
5%
Carboplatin
5%
Castration Resistant Prostate Cancer
5%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
68%
Tracer
60%
Fluorine 18
45%
Urokinase Receptor
33%
Thromboplastin
32%
Malignant Neoplasm
30%
Carbon 11
28%
Blood Clotting Factor 7
24%
Radioligand
24%
Copper 64
22%
Mouse
19%
Integrin
18%
Gallium 68
18%
Receptor Agonist
16%
Dosimetry
15%
Tetraxetan
13%
Human Study
12%
Prostate Cancer
12%
Neuroendocrine Tumor
11%
Minipig
11%
Heart Infarction
11%
Oxime
11%
Receptor
10%
Biological Marker
10%
Biodistribution
9%
Clinical Trial
8%
Azide
8%
Primary Tumor
8%
Safety Assessment
8%
Radiopharmaceutical Agent
7%
Radiation Exposure
7%
Metastasis
6%
Breast Cancer
6%
Glioblastoma
6%
Chemotherapy
5%
Carboplatin
5%
Tumor Invasion
5%
Nicotinamide Phosphoribosyltransferase
5%
Daporinad
5%
Guanosine Phosphate
5%
Bungarotoxin Receptor
5%
Proline
5%
Phenethylamine Derivative
5%
Serotonin 2A Agonist
5%
Paclitaxel
5%
Adrenergic Receptor
5%
Infarction
5%
Trastuzumab
5%
Fluorodeoxyglucose F 18
5%
Pancreas Cancer
5%